Acute Profound Thrombocytopenia After Treatment With Tirofiban and Off-Pump Coronary Artery Bypass Grafting

Beiras-Fernández, Andrés; Kowert, A; Jiru, Pascale; Weis, Marion; Spannagl, Michael; Reichart, Bruno; Schmoeckel, Michael

doi:10.1016/j.athoracsur.2008.06.040

Cited by 11 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative chronic thrombocytopenia is expected to increase the bleeding risk. Other publications report cardiac surgical patients with drug-induced thrombocytopenia [9]. Yet, an assessment of the magnitude of surgical bleeding risk in thrombocytopenic patients is lacking, as reports of cardiac surgery on thrombocytopenic patients are rare.…”

Section: Introductionmentioning

confidence: 99%

Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia

Fox

Hemmann²,

Doss³

et al. 2013

Blood Coagulation &Amp; Fibrinolysis

Self Cite

View full text Add to dashboard Cite

Untreated symptomatic high-grade aortic stenosis remains a lethal disease. Therefore, a comprehensive evaluation is necessary to obtain the best individual treatment for each patient. Recently, transcatheter aortic valve implantation (TAVI) was developed as an innovative therapy for high-risk and inoperable patients. Persistent thrombocytopenia is an established risk for conventional open heart surgery, but is not covered by traditional surgical risk scores. The aim of the study was the investigation of safety and feasibility of TAVI in patients with severe thrombocytopenia. Because of the complicated outcome of patients with persistent thrombocytopenia undergoing heart surgery, we considered all patients with high-grade aortic stenosis and a thrombocyte count of less than 100 per nl as surgical high-risk patients. Out of these high-risk surgical patients, six patients with symptomatic high-grade aortic stenosis and severe thrombocytopenia were deemed to be TAVI candidates and underwent TAVI procedures in 2010 and 2011 (transfemoral: n = 4; transapical: n = 2) at the University Hospital of Frankfurt. The outcome of these patients was analyzed prospectively in order to document safety and feasibility of TAVI in such patients. All TAVI procedures were performed successfully with excellent functional results. There was no occurrence of major or minor bleeding complications, acute renal failure or nosocomial infection. One patient died of an ischemic stroke 12 days after the procedure. The five remaining patients were alive at the 12-month follow-up without relevant cardiovascular events and excellent valve performance. TAVI is an effective and well tolerated method to treat patients with chronic persistent thrombocytopenia and symptomatic high-grade aortic stenosis, and therefore a reasonable alternative to conventional heart surgery in such patients. The indication for TAVI in patients with thrombocytopenia and symptomatic high-grade aortic stenosis might be generated independently from conventional scoring systems.

show abstract

Section: Introductionmentioning

confidence: 99%